Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Cancer Immunol Res. 2016 Nov 8;4(12):1027–1037. doi: 10.1158/2326-6066.CIR-16-0184

Figure 3. Primary dBSM + LPS immunization protects PD-1−/− mice against TA3-Ha challenge and requires B cells.

Figure 3

WT and PD-1−/− mice were immunized with 250 μg dBSM plus 10 μg LPS. A–B) Serum IgM reactivity against dBSM (A) and TA3-Ha cells (B). C–D) Mice were challenged with 104 TA3-Ha cells on d21. Ten days post-challenge, tumor cells in blood were detected using HPA staining and FSC (FSChiHPA+) (C). D) Differences in survival were assessed by Log-rank analysis (n=4–9 naive and 10–14 immune mice/group). Results representative of 3 independent challenge experiments. E) Survival in μMT mice and μMT/PD-1−/− mice immunized and challenged with TA3-Ha cells as above (n=5 mice/genotype). Asterisks(*) indicate significant differences (p <0.05) between mean (±SEM) values for WT and PD-1−/− mice.